Yahoo FinanceAbbvie stock falls amid growing biosimilar competitionApr 26Jared BlikreBy Jared Blikremore_vert
FiercePharmaAbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nodApr 26Zoey BeckerBy Zoey Beckermore_vert
Seeking AlphaAbbVie's Q1: Positive Surprise (NYSE:ABBV)Apr 26Jonathan WeberBy Jonathan Webermore_vert
CNBCHealthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors8 days agoAnnika Kim Constantino & Ashley CapootBy Annika Kim Constantino & Ashley Capootmore_vert
Crain's Chicago BusinessAbbVie raises earnings forecast on strong immunology drug growthApr 26more_vert
MM+M OnlineAbbVie and Gilead post solid Q1 earnings, update full year outlooksApr 26Jack O'BrienBy Jack O'Brienmore_vert
BloombergAbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira LossesApr 26Madison MullerBy Madison Mullermore_vert
MarketWatchAbbVie’s first-quarter results top expectations as arthritis drugs fuel growthApr 26Eleanor LaiseBy Eleanor Laisemore_vert
TheStreetAs AbbVie Beats Expectations, Let's Check the ChartsApr 26Bruce KamichBy Bruce Kamichmore_vert
FinimizeAbbVie Raises Profit Forecast Amid Booming Drug SalesApr 27Carl HazeleyBy Carl Hazeleymore_vert
BioSpaceAbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and RinvoqApr 26Tyler PatchenBy Tyler Patchenmore_vert
U.S News & World Report MoneyDrugmaker AbbVie Expects Humira Volume Erosion to WorsenApr 26Leroy Leo, Christy Santhosh & Devika SyamnathBy Leroy Leo, Christy Santhosh & Devika Syamnathmore_vert
The Business JournalsAbbVie looks to Skyrizi, other drugs to replace blockbuster Humira sales - Chicago Business JournalApr 26more_vert
StreetInsider.comAbbVie (ABBV) hikes 2024 earnings guidance as Q1 beat estimates, shares upApr 26Vahid KaraahmetovicBy Vahid Karaahmetovicmore_vert
Investor's Business DailyAbbVie Stock: Why Humira Biosimilars Won't Undo A Projected $73 Billion In SalesApr 29Allison GatlinBy Allison Gatlinmore_vert
AlphaStreetABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges upApr 26more_vert
GuruFocus.comAbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with Strong Growth in Key ...Apr 27more_vert
Barron'sAbbVie Raises Earnings Guidance Even as Humira Sales Continue to DropApr 26Angela PalumboBy Angela Palumbomore_vert
MarketBeatAbbVie (NYSE:ABBV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPSApr 26more_vert
MorningstarAbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2QApr 26Sabela OjeaBy Sabela Ojeamore_vert
MorningstarAbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar PressureApr 26Damien ConoverBy Damien Conovermore_vert
InvestopediaAbbVie Stock Falls As Company Warns of Continued Humira Sales SlumpApr 26Bill McCollBy Bill McCollmore_vert
Yahoo FinanceAbbVie tries to reassure investors on Humira biosimilar threatApr 26Jonathan D. GardnerBy Jonathan D. Gardnermore_vert
Yahoo FinanceEarnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsApr 30more_vert
Yahoo FinanceWhy AbbVie Stock Stumbled Today Despite the Earnings BeatApr 26James BrumleyBy James Brumleymore_vert
Yahoo FinanceAbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue ChallengesApr 26more_vert
Yahoo FinanceAbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call TranscriptApr 30Insider MonkeyBy Insider Monkeymore_vert
QuartzAbbVie raises full year profit guidance as Humira sales fallApr 26Bruce GilBy Bruce Gilmore_vert
Investor's Business DailyAbbVie Stock Dives Despite 'Firing On All Cylinders' In First QuarterApr 26Allison GatlinBy Allison Gatlinmore_vert
Yahoo Canada FinanceDrugmaker AbbVie expects Humira volume erosion to worsenApr 26Leroy Leo & Christy SanthoshBy Leroy Leo & Christy Santhoshmore_vert
Yahoo Canada FinanceAbbvie stock falls amid growing biosimilar competitionApr 26Jared BlikreBy Jared Blikremore_vert
Investing.com CanadaEarnings call: AbbVie surpasses Q1 expectations, announces CEO transitionApr 29Natashya AngelicaBy Natashya Angelicamore_vert
YahooAbbvie stock falls amid growing biosimilar competitionApr 26Jared BlikreBy Jared Blikremore_vert
YahooAbbvie stock falls amid growing biosimilar competitionApr 26Jared BlikreBy Jared Blikremore_vert
TipRanksAbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition - TipRanks.comApr 26Vince CondarcuriBy Vince Condarcurimore_vert